New research indicates that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who stop traditional lifestyle regimens.
Findings released in a prominent medical journal points out that while overweight people frequently drop substantial amounts of their body weight while on the medication, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing these drugs must be cognizant of the risk of fast rebound weight gain when the medication concludes," warns researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment weight within about 18 months.
Analyzing Approaches
The analysis, which examined dozens of trials involving thousands of participants, contrasted the effects of these new drugs with conventional dieting.
The team note that individuals who lose weight through diet and exercise usually have a more gradual creep back—around 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Doctors propose the way of the jabs accounts for the accelerated rebound.
These medications imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 levels several times higher than the body's typical production could lead to the system to produce less of its own natural GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' results in appetite is uncontrolled, making excessive eating a significant risk."
A Lifelong Disease?
The NHS suggest the injections for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians say that, given the likelihood of weight regain, the treatment should be considered ongoing.
This opinion is reinforced by drug manufacturers, who state that the findings "highlight the chronic character of excess weight," similar to managing conditions like diabetes.
Patient Accounts
People who have stopped the jabs explain a powerful return of hunger.
"It was like a trigger activating and you're instantly starving," said one woman.
This challenge is compounded if patients have not adopted lasting dietary or behavioural modifications during therapy.
Widespread Use
Survey data indicate that a significant number of people in the UK have tried these injections in the last 12 months, with demand being substantial.
- Use is greater among women compared to men.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, researchers emphasize that while the jabs are potent tools for shedding pounds, they are not a standalone solution and maintained weight loss relies on integrated behavioural changes.
